Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Oct 7, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT," is looking at cancer-related fatigue (CRF), which is a common problem for many cancer patients undergoing treatment. The study aims to understand how different biological factors in the body might affect the level of fatigue experienced by patients receiving combined chemotherapy and radiation therapy (CCRT). Researchers will gather information before treatment starts, during treatment, and after treatment is complete to help create models that predict how severe fatigue might be for different individuals.

To participate in this study, you need to be at least 18 years old and have not received any cancer treatments in the past year, except for surgery. You should be willing to complete some questionnaires and provide blood and stool samples at different points during your treatment. The study is open to all genders and is currently recruiting participants. If you join, you’ll be helping to improve our understanding of fatigue in cancer patients, which could lead to better care and support in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the past year except surgery.
• • Participants receiving \>= 15 fractions.
• • Participants is male or female and is \>18 years of age on the day of signing the informed consent.
• • Ability to understand a written informed consent document.
• • Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment.
• • Willing to have medical records reviewed for clinical information.
• • Able to read, write and understand English or Spanish.
• Exclusion Criteria:
• • Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).